Thursday, June 26, 2014
now, inhibition of phosphoinositide 3-kinase-d in cancer has been
limited to leukemias and lymphomas because the isoform is only expressed on
immune cells. A new finding that links the kinase to T cell responses in a
range of solid tumor types could expand use of the inhibitors and launch a new
class of immunotherapies.1
According to Vanhaesebroeck, PI3Kd inhibitors could be used as
immunotherapies in combination with other cancer therapies-including surgery
and radiation-or even as adjuvants to cancer vaccines.
Haas, M.J. SciBX
7(25); doi:10.1038/scibx.2014.726 Published online June 26, 2014
1. Ali, K. et
al. Nature; published online June 11, 2014;
Contact: Bart Vanhaesebroeck, University College London Cancer
Institute, London, U.K.
2. Okkenhaug, K. et al. Science 297,
3. Ali, K. et
al. Nature 431, 1007-1011 (2004)
4. Okkenhaug, K. et al. J. Immunol. 177,
5. Bilancio, A. et al. Blood 107,
6. Fulmer, T. BioCentury 20(9)
A9-A13; Feb. 27, 2012
AND INSTITUTIONS MENTIONED
Babraham Institute, Cambridge, U.K.
South San Francisco, Calif.
Medical Research Council, Harwell, U.K.
Queen Mary University of London, London, U.K.
Rhizen Pharmaceuticals S.A., La Chaux-de-Fonds, Switzerland
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
University College London Cancer Institute, London, U.K.